Update on admission of Subscription Shares

RNS Number : 6147K

Advanced Oncotherapy PLC

03 September 2021

 

3 September 2021

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Update on admission of Subscription Shares

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the announcements released by the Company on 11 August 2021 and 31 August 2021, settlement of the Subscription that is subject to the First Admission is now expected to complete within the next two weeks. Once funds have been received in full, application will be made to the London Stock Exchange for the 82,383,761 Subscription Shares and the 6,470,880 new ordinary shares in respect of the fee arrangements set out in the Company's announcement of 11 August 2021 to be admitted to trading on AIM ("Admission").

The remaining 11,145,405 Subscription Shares that are subject to the Second Admission are expected to be admitted to trading on AIM on or around 1 October 2021.

A further announcement will be made at the appropriate time.

Total voting rights

The Company's issued share capital as at the date of this announcement comprises 350,334,730 ordinary shares of 25p each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 350,334,730. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Defined terms used in this announcement shall have the same meaning as in the announcement of 11 August 2021 unless otherwise defined herein.

- ENDS -

Notes for editors

Advanced Oncotherapy plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking)	Tel: [phone]
SI Capital Ltd (Joint Broker)
Nick Emerson	Tel: [phone]
Jon Levinson	Tel: [phone]
FTI Consulting (Financial PR & IR)	[e-mail]
Simon Conway / Rob Winder	Tel: [phone]

About Advanced Oncotherapy Plc

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

MSCSSLESEEFSEEU